Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Anti‐drug antibody formation following factor VIII (FVIII) replacement therapy is the most
important treatment‐related complication in patients with severe haemophilia A. A significant …

Quantitative abnormalities of the von Willebrand factor–factor VIII (VWF-FVIII) complex
associate with inherited bleeding or thrombotic disorders. Receptor-mediated interactions …

Despite> 80 years of clinical experience with coagulation factor VIII (FVIII) inhibitors,
surprisingly little is known about the in vivo mechanism of this most serious complication of …

Adeno-associated virus (AAV) vector gene therapy is a promising treatment for a variety of
genetic diseases, including hemophilia. Systemic administration of AAV vectors is …

Essentials• CLEC4M is an endocytic receptor for factor FVIII.• CLEC4M interacts with FVIII in
a VWF‐dependent and independent manner.• CLEC4M binds to mannose‐containing …

Quantitative abnormalities in factor VIII (FVIII) and its binding partner, von Willebrand factor
(VWF), are associated with an increased risk of bleeding or thrombosis, and pathways that …

Hemophilia A is an X-linked hereditary disorder that results from deficient coagulation factor
VIII (FVIII) activity, leading to spontaneous bleeding episodes, particularly in joints and …

Recombinant adeno-associated virus (rAAV) platforms hold promise for in vivo gene therapy
but are undermined by the undesirable transduction of antigen presenting cells (APCs) …

The development of neutralizing anti-FVIII antibodies (inhibitors) is a major complication of
FVIII protein replacement therapy in patients with hemophilia A (HA). Although multiple lines …